Tavor

Depression

Rakitzi, StavroulaPhase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

72 Active assets in the Depression cohort.

Asset / Sponsor	Phase	Rating
S-Ketamine Chinese PLA General Hospital	Phase 4	BBB
Cipralex Poznan University of Medical Sciences	Phase 4	BBB
Opc-34712 Dr. Albert Kar-Kin Chung	Phase 4	BBB
VENLOR Janssen Research & Development, LLC	Phase 4	BBB
LITHIUM, ELEMENTAL Rakitzi, Stavroula	Phase 4	BBB

View all 50 →

Same molecule, other indications

Tavor is also rated in:

bipolar disorderDormant

BB

Indicative ·

65 / 100

Bipolar DisorderDormant

B

Indicative ·

63 / 100

treatment-refractory schizophreniaDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.